SCHEMBL7124527

SCHEMBL7124527

OC[C@H]1OC(c2cc3ccc4cccc5ccc(c2)c3c45)C[C@@H]1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 1/20 0.37
NR2F2 P24468 1/20 0.37
SLC5A2 P31639 7/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
PDE4D Q08499 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GJA1 P17302 1/20 0.33
GJB2 P29033 1/20 0.33
ADRB1 P08588 1/20 0.32
DNMT1 P26358 1/20 0.32
ALDH1A1 P00352 1/20 0.31
CYP1A1 P04798 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
CYP1B1 Q16678 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7131697 0.89 GALR3 (0.35) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL12766796 0.82 GALR3 (0.36) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL15255719 0.82 GALR3 (0.36) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL26231584 0.82 GALR3 (0.36) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL14211493 0.82 GALR3 (0.36) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL24687116 0.82 GALR3 (0.36) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL12464627 0.82 GALR3 (0.36) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL5048342 0.82 GALR3 (0.36) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL22334100 0.82 GALR3 (0.36) GALR3NR2F2SLC5A2NCOA1NCOA3
SCHEMBL14089084 0.81 CYP1A2 (0.39) GALR3NR2F2SLC5A2NCOA1NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670193-B2 Coupling with organometallic compound; emission light RESEARCH CORPORATION TECHNOLOGIES, INC. 2003-12-30 US disclosed
US-6479650-B1 Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same RESEARCH CORPORATION TECHNOLOGIES, INC. 2002-11-12 US disclosed
US-20020160411-A1 Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2002-10-31 US disclosed
WO-2001044220-A2 FLUORESCENT NUCLEOSIDE ANALOGS AND COMBINATORIAL FLUOROPHORE ARRAYS COMPRISING SAME RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020160411-A1 Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same DERA, FBL, DUT GALR3 1477/4885NR2F2 3566/4885SLC5A2 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.